



Advanced Diagnostic  
Laboratories

Dear Valued Client:

Effective Friday, Feb. 24, 2023, National Jewish Health Advanced Diagnostic Laboratories launched a new panel of tests to evaluate alpha-1 antitrypsin deficiency. The panel was developed in collaboration with our own world-renowned physicians utilizing our outstanding biobank of samples. This new panel tests level and genotype, with reflex to phenotype as needed.

Our new genotyping test identifies the presence of 20 single nucleotide polymorphisms (SNPs) in the human SERPINA1 gene, including 19 mutations and the major normal allele (M). Mutations can be detected in samples of blood, buccal swabs, or dried blood spots. This genotyping can reflex to Pi typing based on our new National Jewish Health algorithm and is the most comprehensive test available commercially. We also plan to offer reflex testing for whole exome sequencing in the near future.

The test code has been updated to reflect the new platform:

- **Test Code**  
Code: A1LGP  
Test Name: Alpha-1 Antitrypsin: Levels, Genotype, and Phenotype (as needed per algorithm)
- **Additional Improvement**  
One test code for all alpha-1 antitrypsin testing

Please contact our Client Service Team at 800.550.6227 or [clinreflabs@njhealth.org](mailto:clinreflabs@njhealth.org) if you have any questions or concerns.

Sincerely,

A handwritten signature in blue ink, appearing to read "Steve Groshong".

Steve Groshong, MD, PhD  
Medical Director, Advanced Diagnostic Laboratories  
National Jewish Health